Delavirdine mesylate data

Preliminary data from 1,900 patients in two randomized, double-blind North American Phase II/III trials showed that treated patients who achieved a sustained drop in viral burden were less likely to progress to AIDS defining events or death.

In addition, Pharmacia & Upjohn said that baseline plasma RNA viral load directly correlated with disease progression. ...